KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Receives Average Recommendation of “Buy” from Analysts

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) has earned an average rating of “Buy” from the eight brokerages that are covering the stock, Marketbeat.com reports. Seven analysts have rated the stock with a buy rating and one has issued a strong buy rating on the company. The average 1-year price objective among brokers that have issued a report on the stock in the last year is $24.83.

Several equities research analysts have recently issued reports on KALV shares. HC Wainwright reaffirmed a “buy” rating and issued a $20.00 price target on shares of KalVista Pharmaceuticals in a research report on Friday, March 14th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of KalVista Pharmaceuticals in a research report on Monday, December 9th. JMP Securities assumed coverage on KalVista Pharmaceuticals in a research report on Friday, January 31st. They issued an “outperform” rating and a $19.00 price objective for the company. Citizens Jmp upgraded shares of KalVista Pharmaceuticals to a “strong-buy” rating in a research note on Friday, January 31st. Finally, Bank of America began coverage on shares of KalVista Pharmaceuticals in a research note on Wednesday, December 18th. They set a “buy” rating and a $22.00 target price for the company.

Insider Buying and Selling at KalVista Pharmaceuticals

In related news, major shareholder Venrock Healthcare Capital Par purchased 43,707 shares of the firm’s stock in a transaction that occurred on Thursday, January 30th. The shares were acquired at an average price of $8.76 per share, with a total value of $382,873.32. Following the purchase, the insider now directly owns 4,986,480 shares in the company, valued at $43,681,564.80. This represents a 0.88 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CEO Benjamin L. Palleiko sold 5,104 shares of the company’s stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $9.82, for a total value of $50,121.28. Following the completion of the sale, the chief executive officer now owns 278,855 shares in the company, valued at $2,738,356.10. This trade represents a 1.80 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have acquired 236,055 shares of company stock valued at $2,162,146 and have sold 17,292 shares valued at $184,625. Insiders own 10.50% of the company’s stock.

Institutional Investors Weigh In On KalVista Pharmaceuticals

Several institutional investors and hedge funds have recently made changes to their positions in the company. Aquatic Capital Management LLC bought a new position in KalVista Pharmaceuticals during the 4th quarter valued at about $44,000. Tower Research Capital LLC TRC increased its holdings in shares of KalVista Pharmaceuticals by 666.9% during the fourth quarter. Tower Research Capital LLC TRC now owns 6,327 shares of the specialty pharmaceutical company’s stock worth $54,000 after buying an additional 5,502 shares in the last quarter. Legal & General Group Plc raised its stake in shares of KalVista Pharmaceuticals by 22.5% in the fourth quarter. Legal & General Group Plc now owns 8,144 shares of the specialty pharmaceutical company’s stock valued at $69,000 after acquiring an additional 1,494 shares during the last quarter. Martin Worley Group acquired a new position in shares of KalVista Pharmaceuticals in the 4th quarter worth approximately $86,000. Finally, China Universal Asset Management Co. Ltd. grew its position in KalVista Pharmaceuticals by 24.7% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 10,329 shares of the specialty pharmaceutical company’s stock worth $87,000 after acquiring an additional 2,043 shares during the last quarter.

KalVista Pharmaceuticals Trading Down 3.3 %

NASDAQ:KALV opened at $11.93 on Friday. The firm has a market capitalization of $593.11 million, a PE ratio of -3.28 and a beta of 0.76. KalVista Pharmaceuticals has a 1 year low of $7.30 and a 1 year high of $15.50. The firm’s fifty day simple moving average is $10.56 and its 200 day simple moving average is $10.26.

KalVista Pharmaceuticals Company Profile

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company’s product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).